Comparative analysis of the range list of medicines for the treatment of arterial hypertension in accordance with domestic and international clinical guidelines

Abstract

Cardiovascular disease is the most common cause of death and disability worldwide. There are more than 12 million patients with hypertension in Ukraine. Timely prescription of medicines patients with AH in accordance with current clinical guidelines significantly improves the quality of life and survival of patients. The purpose of the study was to conduct a comparative analysis of the international and domestic range of modern medicines for the treatment of hypertension according to INN and ATC-classification and to investigate the status of their registration and inclusion in the reimbursement lists in Ukraine in order to determine the potential physical availability of drugs for the treatment of hypertension. An analysis of the domestic regulatory framework showed that international CG for the treatment of hypertension and national CPs can be used in Ukraine. The content analysis of the CG showed that international CG include classes of medicines for initial and maintenance therapy of hypertension: ACE inhibitors, ARBs, diuretics (thiazide and thiazide-like), calcium antagonists and beta-blockers, while preference is given to combinations of these drugs due to better adherence patients for treatment. It was found that according to the ATC classification, 41 ACE inhibitors and their combinations are represented on the international pharmaceutical market for the treatment of hypertension; of which 16 are single-component drugs, 25 are combined; ARB II and their combinations ‒ 32, single-component 10, combinations ‒ 22; calcium channel blockers and their combinations ‒ 21, single-component ‒ 18, combinations ‒ 2, thiazide diuretics ‒ 10, thiazide-like diuretics ‒ 11. An analysis of the status of registration in Ukraine according to certain INN and ATC classification showed that 56 drugs were registered, which is 48.69% of the possible 115 (drugs and ACE inhibitors and their combinations 22 (53.65%), ARBs II and their combinations 21 (65.63%); CCBs and their combinations ‒ 8 (38.10%); thiazide diuretics ‒ 1 (10%), thiazide-like diuretics ‒ 3 (27.27%)).

Keywords

• range of medicines
• arterial hypertension
• reimbursement